GRDN trades 7.9% below Wall Street's consensus target of $50.67.
Last 12 months price action with 12-month analyst target path
The base valuation assumes GRDN achieves its forward estimates and maintains a stable P/E multiple of 36.1x. This scenario reflects the blended consensus of 4 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 21, 2026, Guardian Pharmacy Services, Inc. (GRDN) has a Wall Street consensus price target of $50.67, based on estimates from 4 covering analysts. With the stock currently trading at $46.94, this represents a potential upside of +7.9%. The company has a market capitalization of $2.97B.
Analyst price targets range from a low of $49.00 to a high of $52.00, representing a 6% spread in expectations. The median target of $51.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 4 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, GRDN trades at a trailing P/E of 40.1x and forward P/E of 36.1x. The forward PEG ratio of 1.92 indicates reasonable valuation for growth. Analysts expect EPS to grow +11.3% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $34.69, with bear and bull scenarios of $21.85 and $45.70 respectively. Model confidence stands at 53/100, reflecting moderate uncertainty in projections.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
OMCLOmnicell, Inc. | $1.5B | $32.51 | $57.50 | +76.9% | Buy | 13.1x | 20 |
CVSCVS Health Corp. | $103.1B | $80.84 | $109.89 | +35.9% | Buy | 10.0x | 41 |
MCKMcKesson Corporation | $124.8B | $1069.43 | $983.13 | -8.1% | Buy | 24.0x | 31 |
CAHCardinal Health, Inc. | $63.9B | $272.81 | $279.33 | +2.3% | Buy | 21.7x | 33 |
VEEVVeeva Systems Inc. | $43.2B | $266.22 | $300.50 | +12.9% | Buy | 28.8x | 43 |
ENSGThe Ensign Group, Inc. | $10.3B | $176.32 | $223.25 | +26.6% | Buy | 22.1x | 13 |
ADUSAddus HomeCare Corporation | $2.3B | $122.50 | $128.75 | +5.1% | Buy | 17.4x | 18 |
BKDBrookdale Senior Living Inc. | $2.1B | $8.86 | $19.50 | +120.1% | Buy | 295.3x | 12 |
Quick answers to the most common questions about buying GRDN stock.
The consensus price target for GRDN is $50.67, close to the current price of $46.94 (7.9% implied move). Based on 4 analyst estimates, the stock appears fairly valued near current levels.
GRDN has a consensus rating of "Buy" based on 4 Wall Street analysts. The rating breakdown is predominantly bullish, with 4 Buy/Strong Buy ratings. The consensus 12-month price target of $50.67 implies 7.9% upside from current levels.
At a forward P/E of 36.0522x, GRDN trades at a premium valuation. The consensus price target of $50.67 (7.9% upside) suggests analysts may view current valuations as stretched.
The most bullish Wall Street analyst has a price target of $52 for GRDN, while the most conservative target is $49. The consensus of $50.67 represents the median expectation. Our quantitative valuation model projects a bull case target of $46 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
GRDN is lightly followed, with 4 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 4 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month GRDN stock forecast based on 4 Wall Street analysts shows a consensus price target of $50.67, with estimates ranging from $49 (bear case) to $52 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $35, with bear/bull scenarios of $22/$46.
Our quantitative valuation model calculates GRDN's fair value at $35 (base case), with a bear case of $22 and bull case of $46. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 53/100.
GRDN trades at a forward P/E ratio of 36.1x based on next-twelve-months earnings estimates compared to a trailing P/E of 40.1x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
GRDN appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $50.67 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
GRDN analyst price targets range from $49 to $52, a 6% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $50.67 consensus represents the middle ground. Our model's $22-$46 range provides an independent fundamental perspective.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.